LEF1 and triple-A syndrome: Compared with the control group, the expression of LEF1 was significantly upregulated in the disease group (Figure 4B), and the area under the curve (AUCs) of LEF1 in both datasets was > 0.8, indicating that LEF1 can be used as a potential biomarker for the diagnosis of AAA patients (Figure 4C).